Title :

Efficacy and safety of rituximab-based treatments in angioedema with acquired C1 inhibitor deficiency.

Author(s) :

Kalmi, Galith [Auteur]
CHU Saint-Antoine [AP-HP]
Nguyen, Yann [Auteur]
Hôpital Beaujon [AP-HP]
Amarger, Stephanie [Auteur]
CHU Gabriel Montpied [Clermont-Ferrand]
Aubineau, Magali [Auteur]
Hospices Civils de Lyon [HCL]
Bibes, Beatrice [Auteur]
Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou]
Blanchard-Delaunay, Claire [Auteur]
Centre Hospitalier Georges Renon [Niort] [CH Georges Renon Niort]
Boccon-Gibod, Isabelle [Auteur]
Centre de référence national des angiœdèmes [CREAK]
Bouillet, Laurence [Auteur]
Centre Hospitalier Universitaire [CHU Grenoble] [CHUGA]
Centre de référence national des angiœdèmes [CREAK]
Coppo, Paul [Auteur]
CHU Saint-Antoine [AP-HP]
Dalmas, Marie-Caroline [Auteur]
Centre Hospitalier Universitaire [Strasbourg] [CHU Strasbourg]
Debord-Peguet, Sophie [Auteur]
Hospices Civils de Lyon [HCL]
Defendi, Federica [Auteur]
Centre Hospitalier Universitaire [CHU Grenoble] [CHUGA]
Demoreuil, Claire [Auteur]
Hôpital de la Cavale Blanche - CHRU Brest [CHU - BREST ]
Du-Thanh, Aurélie [Auteur]
Centre Hospitalier Régional Universitaire [Montpellier] [CHRU Montpellier]
Gayet, Stephanie [Auteur]
Hôpital de la Timone [CHU - APHM] [TIMONE]
Hadjadj, Jérôme [Auteur]
CHU Saint-Antoine [AP-HP]
Jeandel, Pierre-Yves [Auteur]
Centre Hospitalier Universitaire de Nice [CHU Nice]
Launay, David [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Ly, Kim Heang [Auteur]
CHU Limoges
Mc Avoy, Chloé [Auteur]
CHU Saint-Antoine [AP-HP]
Niault, Mathilde [Auteur]
Groupe Hospitalier Bretagne Sud [GHBS]
Ollivier, Yann [Auteur]
CHU Caen
CHU Saint-Antoine [AP-HP]
Pelletier, Fabien [Auteur]
Centre Hospitalier Régional Universitaire de Besançon [CHRU Besançon]
Porneuf, Marc [Auteur]

Roos-Weil, Damien [Auteur]

Fain, Olivier [Auteur]
CHU Saint-Antoine [AP-HP]
Gobert, Delphine [Auteur]
CHU Saint-Antoine [AP-HP]

Journal title :

Journal of Allergy and Clinical Immunology: In Practice

Abbreviated title :

J Allergy Clin Immunol Pract

Publication date :

2023-10-18

ISSN :

2213-2201

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

Angioedema (AE) due to acquired C1-inhibitor (C1-INH) deficiency (AAE–C1-INH) is related to excessive consumption of C1-INH or to anti–C1-INH antibodies, and is frequently associated with lymphoproliferative syndromes or ...
Show more >Angioedema (AE) due to acquired C1-inhibitor (C1-INH) deficiency (AAE–C1-INH) is related to excessive consumption of C1-INH or to anti–C1-INH antibodies, and is frequently associated with lymphoproliferative syndromes or monoclonal gammopathies. Standard of care for prophylactic treatment in this condition is not established. Rituximab may be effective to prevent attacks, especially if the lymphoid hemopathy is controlled, but data are scarce. Objective To evaluate efficacy of rituximab in AAE–C1-INH. Methods A retrospective multicenter study was carried out in France, including patients with AAE–C1-INH treated with rituximab between April 2005 and July 2019. Results Fifty-five patients with AAE–C1-INH were included in the study, and 23 of them had an anti–C1-INH antibody. A lymphoid malignancy was identified in 39 patients, and a monoclonal gammopathy in 9. There was no associated condition in 7 cases. Thirty patients received rituximab alone or in association with chemotherapy (n = 25). Among 51 patients with available follow-up, 34 patients were in clinical remission and 17 patients had active AE after a median follow-up of 3.9 years (interquartile range, 1.5-7.7). Three patients died. The presence of anti–C1-INH antibodies was associated with a lower probability of AE remission (hazard ratio, 0.29 [95% CI, 0.12-0.67]; P = .004). Relapse was less frequent in patients with lymphoma (risk ratio, 0.27 [95% CI, 0.09-0.80]; P = .019) and in patients treated with rituximab and chemotherapy (risk ratio, 0.31 [95% CI, 0.12-0.79]; P = .014). Conclusions Rituximab is an efficient and well-tolerated therapeutic option in AE, especially in lymphoid malignancies and in the absence of detectable anti–C1-INH antibodies.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

Université de Lille
Inserm
CHU Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Submission date :

2024-01-11T22:09:45Z
2024-02-28T12:44:41Z